Home Journals Articles Updates About
CN
image
收藏切换
Efficacy and safety of ceftolozane/tazobactam in the treatment of gram-negative bacterial infections: A systematic review and Meta-analysis
收藏切换
PDF
Yun-pei ZHAO1, 2, Jun YANG1, Ge YANG1, Jie QIN2, Lin-li XIE1, Yong-chuan CHEN1
Chinese Journal of Clinical Pharmacology | 2025, 41(20) : 2941 - 2947
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(20): 2941-2947
• Reader’s Field •
Efficacy and safety of ceftolozane/tazobactam in the treatment of gram-negative bacterial infections: A systematic review and Meta-analysis
Full
Yun-pei ZHAO1, 2, Jun YANG1, Ge YANG1, Jie QIN2, Lin-li XIE1, Yong-chuan CHEN1
Affiliations
  • 1.Department of Pharmacy, the First Affiliated Hospital of Army Medical University, Chongqing 400038, China
  • 2.The 74th Group Army Hospital of PLA, Guangzhou 510000, Guangdong Province, China
Published: 2025-10-28 doi: 10.13699/j.cnki.1001-6821.2025.20.016
Outline
收藏切换
Objective

This study systematically evaluated its clinical efficacy and safety of ceftolozane/tazobactam for gram-negative bacterial (GNB) infections.

Methods

Clinical studies on ceftolozane/tazobactam for GNB infections were retrieved from PubMed, Embase, Cochrane Library, CNKI, VIP, and WanFang databases from inception to April 2025. Study quality was assessed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using RevMan 5.4.1.

Results

Twenty-two studies involving 5 728 patients were included. Ceftolozane/tazobactam demonstrated superior clinical efficacy against Pseudomonas aeruginosa infections compared to control drugs (OR=1.61; 95% CI: 1.07-2.42; I2=60%; P=0.02) and significantly higher bacterial eradication rates (OR=1.27; 95% CI: 1.05-1.55; I2=11%; P=0.01). No significant differences were observed in adverse event rates (OR=0.90; 95% CI: 0.70-1.15; I2=55%; P=0.40), serious adverse event rates (OR=0.83; 95% CI: 0.53-1.29; I2=73%; P=0.40), or all-cause mortality (OR=0.92; 95% CI: 0.78-1.10; I2=0%; P=0.37).

Conclusion

For GNB infections, ceftolozane/tazobactam exhibits non-inferior clinical efficacy and safety to comparator drugs with higher bacterial eradication rates. It may represent a preferred alternative for Pseudomonas aeruginosa nfections.

ceftolozane/tazobactam  /  gram-negative bacteria  /  efficacy  /  safety  /  Meta-analysis
Yun-pei ZHAO, Jun YANG, Ge YANG, Jie QIN, Lin-li XIE, Yong-chuan CHEN. Efficacy and safety of ceftolozane/tazobactam in the treatment of gram-negative bacterial infections: A systematic review and Meta-analysis[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (20) : 2941 -2947 . DOI: 10.13699/j.cnki.1001-6821.2025.20.016
Appendix
Less
Year 2025 volume 41 Issue 20
PDF
174
33
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.20.016
  • Receive Date：2025-07-16
  • Online Date：2026-08-05
  • Published：2025-10-28
Article Data
Affiliations
History
  • Received：2025-07-16
Affiliations
    1.Department of Pharmacy, the First Affiliated Hospital of Army Medical University, Chongqing 400038, China
    2.The 74th Group Army Hospital of PLA, Guangzhou 510000, Guangdong Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.20.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House